Katholieke Universiteit Leuven

K.u. Leuven Research & Development

Università Di Siena

Chantal Mathieu

Roger Bouillon

Mark Waer

Guido Sebastiani

Giuliana Ventriglia

Francesco Dotta

Constantia Gysemans

The invention relates to an in-vitro method for identifying a diabetic patient as responder or non-responder to a treatment of Proinsulin, Interleukin 10 and anti-CD3, based on the expression level of at least 1 microRNA, selected from the group consisting of miR-365, miR-34a, miR-193b and miR-125a, in a sample from the diabetic patient prior to said treatment.

Biomarkers for diabetes therapy

A method for modulating the immune system by administering one or more vitamin D (analogues) to a subject in need of immune therapy, which method may (but need not) include simultaneous treatment with a second immune system modulating active agent. Preferably, the treatment method is used to induce primary or secondary prevention of type I diabetes in a subject susceptible to type I diabetes. Administration of the vitamin D (analogues) is enteral or parenteral.

Methods and compositions for primary and secondary prevention of

Growing community of inventors

Buizingen, Belgium

Chantal Mathieu